Connect Biopharma's Rademikibart Shows Strong Phase 3 Results in Atopic Dermatitis
Event summary
- Rademikibart achieved 96.6% EASI-75 response rate and 85.3% EASI-90 response rate in a 52-week Phase 3 study for moderate-to-severe atopic dermatitis.
- The study demonstrated low rates of conjunctivitis, comparable to placebo, and favorable safety profile.
- Results were presented at the 2026 American Academy of Dermatology Annual Meeting on March 28, 2026.
- Connect Biopharma stands to receive up to $110 million in milestone payments and royalties from Simcere for Greater China rights.
The big picture
Connect Biopharma's positive Phase 3 results for rademikibart in atopic dermatitis position the company to potentially capture a significant share of the growing dermatology market. The strong efficacy and safety data, combined with the strategic partnership with Simcere, could accelerate rademikibart's path to commercialization in Greater China and beyond. The results also highlight the potential for rademikibart to become a best-in-class treatment option, addressing a substantial unmet need in moderate-to-severe atopic dermatitis.
What we're watching
- Regulatory Pathway
- Whether Simcere's pending NDA for rademikibart in China will receive approval by the NMPA and the timing of any such approval.
- Commercialization Strategy
- The pace at which Connect Biopharma can leverage these results to secure additional partnerships or expand into other indications outside of China.
- Competitive Positioning
- How rademikibart's differentiated profile, particularly its low rates of conjunctivitis, will position it against existing and emerging therapies in the atopic dermatitis market.